Page 43 - Bio Developments News Today

Positive study results said to support deployment of assay system in cancer drug clinical trials New research findings suggest that an immunotherapy assay enables determination of PD-L1 status in a high percentage of cancer patients and could guide personalized treatment selection. Liquid biopsy company, ANGLE, is presenting the results of two studies evaluating the effectiveness of two assays at the virtual American Association for Cancer Research Conference (AACR)...

When BioNTech calls 2020 a transformational year, it’s something of an understatement: with the company partnering with Pfizer to bring the first mRNA COVID-19 vaccine to market. So what’s next? BioNTech pledges to accelerate and expand its innovation pipeline with projects such as new mRNA vaccines and a boosted oncology pipeline to ‘build a 21st century global immunotherapy powerhouse’. The German biotech was founded in 2008 in Mainz by husband and wife tea...

Pfizer and BioNTech ramp up COVID-19 vaccine production to 2.5 billion doses Pfizer and BioNTech expect to expand COVID-19 vaccine manufacturing capacity to up to 2.5 billion doses by the end of 2021, thanks to the optimization of production processes and the recent initiation of production in Marburg, Germany. Earlier this year the companies had set the target of producing 2 billion doses in 2021, which it has now upped to 2.5 billion. “The increase is driven by ...

Ajinomoto and Bright Peak partner to develop immunocytokines Ajinomoto Co., Inc, and Bright Peak Therapeutics Inc. have entered into a research collaboration and license agreement to develop immunocytokines. Basel, Switzerland based, Bright Peak, is a biotechnology company developing next generation immunotherapies for cancer and autoimmune disease. The deal sees it incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation technology, for the dev...

Precigen claims breakthroughs in CAR T cell therapy manufacturing that will eventually allow cancer centers to enable treatments earlier and at a lower cost. Chimeric antigen receptor (CAR) T cell therapy continues to change the cancer treatment paradigm, with four therapies, to date, approved in the US. While opportunities continue to emerge for new cancer targets, CAR T treatments, up to this point, are, however, associated with some major challenges.  Conventiona...

MRNA technology enabled rapid SARS-CoV-2 vaccine development. How can the biopharmaceutical industry improve before the next pandemic?

Baxter BioPharma Solutions to perform fill/finish services for Moderna’s COVID-19 vaccine Baxter BioPharma Solutions will provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of Moderna’s COVID-19 vaccine this year. The agreement will help Moderna scale up manufacturing capacity in the US as it seeks to reach its target of 1 billion doses globally in 2021. Manufacture will take place at BioPharma Solutions...

A laboratory study published in the New England Journal of Medicine shows the Pfizer/BioNTech COVID-19 vaccine was able to neutralize the emerging Brazil coronavirus strain.

Researchers from Cleveland Clinic's Global Center for Pathogen Research & Human Health, who have developed the nanotechnology based vaccine, say it has shown strong efficacy in preclinical disease models.

Using mRNA technology to develop vaccines for HIV and beyond ConserV Bioscience and eTheRNA immunotherapies are to collaborate on development of mRNA vaccines for infectious diseases. The initial focus of their alliance will be on the development and evaluation of mRNA vaccine formulations against human immunodeficiency virus (HIV), with the objective of identifying a lead formulation to move forward to clinical development. An effective vaccine to prevent HIV infe...